All Stories

  1. Gammaplex® 5 and 10% in the treatment of primary immunodeficiency and chronic immune thrombocytopenic purpura

    Article • Immunotherapy, September 2017, Future Medicine

    Dr Richard L Wasserman

  2. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

    Article • Immunotherapy, September 2017, Future Medicine

    Dr Richard L Wasserman

  3. Treatment with oleic acid reduces IgE binding to peanut and cashew allergens

    Article • Food Chemistry, August 2015, Elsevier

    Dr Richard L Wasserman

  4. Efficacy, safety, and tolerability of IVIG-SN in patients with primary immunodeficiency

    Article • LymphoSign Journal, March 2015, LymphoSign Journal Limited Partnership

    Dr Richard L Wasserman

  5. Tolerance to Allergenic Foods Following Food Oral Immunotherapy (FOIT)

    Article • Journal of Allergy and Clinical Immunology, February 2015, Elsevier

    Dr Richard L Wasserman

  6. Single Practice Six-Year Experience Treating Food Allergy with Oral Immunotherapy

    Article • Journal of Allergy and Clinical Immunology, February 2015, Elsevier

    Dr Richard L Wasserman

  7. Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)

    Article • Journal of Allergy and Clinical Immunology, February 2015, Elsevier

    Dr Richard L Wasserman

  8. Pharmacokinetics of RI-002, an Investigational Igiv Preparation

    Article • Journal of Allergy and Clinical Immunology, February 2015, Elsevier

    Dr Richard L Wasserman

  9. Subcutaneous immunoglobulin: facilitated infusion and advances in administration

    Article • Clinical & Experimental Immunology, December 2014, Wiley

    Dr Richard L Wasserman

  10. Hizentra for the treatment of primary immunodeficiency

    Article • Expert Review of Clinical Immunology, September 2014, Taylor & Francis

    Dr Richard L Wasserman

  11. Decreased Immunoglobulin E (IgE) Binding to Cashew Allergens following Sodium Sulfite Treatment and Heating

    Article • Journal of Agricultural and Food Chemistry, July 2014, American Chemical Society (ACS)

    Dr Richard L Wasserman

  12. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies

    Article • Immunotherapy, May 2014, Future Medicine

    Dr Richard L Wasserman

  13. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency

    Article • Expert Review of Clinical Immunology, February 2014, Taylor & Francis

    Dr Richard L Wasserman

  14. Single Practice Five-Year Experience Treating Food Allergy With Oral Immunotherapy: Efficacy and Epinephrine Treated Reactions

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  15. Single Practice, Five-Year Experience Treating Food Allergy With Oral Immunotherapy (FOIT): Successes and Failures

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  16. Single Practice Five Year Experience Treating Food Allergy With Oral Immunotherapy (FOIT): Effect On Antigen Specific IgE (asIgE)

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  17. Effect Of Oleic Acid On The Allergenic Properties Of Peanut and Cashew Allergens

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  18. Retrospective Analysis Of The Clinical Utility Of Biweekly Dosing With High-Concentration Subcutaneous Immunoglobulin In 10 Patients With Primary Immunodeficiency

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  19. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease

    Article • Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  20. Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)

    Article • Journal of Allergy and Clinical Immunology, February 2014, Elsevier

    Dr Richard L Wasserman

  21. Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes

    Article • Journal of Clinical Immunology, January 2014, Springer Science + Business Media

    Dr Richard L Wasserman

  22. Oral Immunotherapy for Peanut Allergy: Multipractice Experience With Epinephrine-treated Reactions

    Article • The Journal of Allergy and Clinical Immunology In Practice, January 2014, Elsevier

    Dr Richard L Wasserman

  23. In vitro digestion of soluble cashew proteins and characterization of surviving IgE-reactive peptides

    Article • Molecular Nutrition & Food Research, December 2013, Wiley

    Dr Richard L Wasserman

  24. Case Studies

    Article • Journal of Clinical Immunology, August 2013, Springer Science + Business Media

    Dr Richard L Wasserman

  25. Characterization of the Effects of Proteolysis and Reduction On Cashew Allergens

    Article • Journal of Allergy and Clinical Immunology, February 2013, Elsevier

    Dr Richard L Wasserman

  26. Long-Term Efficacy and Tolerability of 20% Scig in the Treatment of Patients with Primary Immunodeficiency Disease

    Article • Journal of Allergy and Clinical Immunology, February 2013, Elsevier

    Dr Richard L Wasserman

  27. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies

    Article • Pediatric Allergy and Immunology, November 2012, Wiley

    Dr Richard L Wasserman

  28. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

    Article • Journal of Allergy and Clinical Immunology, October 2012, Elsevier

    Dr Richard L Wasserman

  29. Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema Attacks

    Article • Advances in Therapy, September 2012, Springer Science + Business Media

    Dr Richard L Wasserman

  30. C1-inhibitor therapy for hereditary angioedema attacks: Prospective patient assessments of health-related quality of life

    Article • Allergy and Asthma Proceedings, September 2012, Oceanside Publications Inc.

    Dr Richard L Wasserman

  31. Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

    Article • Journal of Clinical Immunology, July 2012, Springer Science + Business Media

    Dr Richard L Wasserman

  32. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks

    Article • Allergy and Asthma Proceedings, July 2012, Oceanside Publications Inc.

    Dr Richard L Wasserman

  33. Discussion

    Article • Immunology and Allergy Clinics of North America, June 2012, Elsevier

    Dr Richard L Wasserman

  34. Introduction

    Article • Immunology and Allergy Clinics of North America, June 2012, Elsevier

    Dr Richard L Wasserman

  35. Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

    Article • Journal of Clinical Immunology, March 2012, Springer Science + Business Media

    Dr Richard L Wasserman

  36. Safety ofL-proline as a stabilizer for immunoglobulin products

    Article • Expert Review of Clinical Immunology, February 2012, Taylor & Francis

    Dr Richard L Wasserman

  37. Diagnosis and treatment of primary immunodeficiency disease: the role of the otolaryngologist

    Article • American Journal of Otolaryngology, July 2011, Elsevier

    Dr Richard L Wasserman

  38. Reply

    Article • Journal of Allergy and Clinical Immunology, July 2011, Elsevier

    Dr Richard L Wasserman

  39. Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency

    Article • Clinical Pharmacokinetics, June 2011, Springer Science + Business Media

    Dr Richard L Wasserman

  40. Author Response

    Article • Annals of Allergy Asthma & Immunology, April 2011, Elsevier

    Dr Richard L Wasserman

  41. Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

    Article • Journal of Clinical Immunology, March 2011, Springer Science + Business Media

    Dr Richard L Wasserman

  42. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks

    Article • Annals of Allergy Asthma & Immunology, January 2011, Elsevier

    Dr Richard L Wasserman

  43. Office-based oral immunotherapy for food allergy is safe and effective

    Article • Journal of Allergy and Clinical Immunology, January 2011, Elsevier

    Dr Richard L Wasserman

  44. Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity

    Article • Allergy and Asthma Proceedings, January 2011, Oceanside Publications Inc.

    Dr Richard L Wasserman

  45. Recurrent Granulibacter bethesdensis Infections and Chronic Granulomatous Disease

    Article • Emerging Infectious Diseases, September 2010, Centers for Disease Control and Prevention (CDC)

    Dr Richard L Wasserman

  46. Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks

    Article • Annals of Allergy Asthma & Immunology, August 2010, Elsevier

    Dr Richard L Wasserman

  47. Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary Angioedema

    Article • Journal of Clinical Immunology, July 2010, Springer Science + Business Media

    Dr Richard L Wasserman

  48. Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency

    Article • Journal of Clinical Immunology, May 2010, Springer Science + Business Media

    Dr Richard L Wasserman

  49. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies

    Article • Clinical Immunology, May 2010, Elsevier

    Dr Richard L Wasserman

  50. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks

    Article • Journal of Allergy and Clinical Immunology, October 2009, Elsevier

    Dr Richard L Wasserman

  51. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency

    Article • European Journal of Pharmaceutical Sciences, June 2009, Elsevier

    Dr Richard L Wasserman

  52. Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

    Article • Journal of Clinical Immunology, September 2008, Springer Science + Business Media

    Dr Richard L Wasserman

  53. Real-world assessment of a metered-dose inhaler with integrated dose counter

    Article • Allergy and Asthma Proceedings, November 2006, Oceanside Publications Inc.

    Dr Richard L Wasserman

  54. Intrainfusion and postinfusion adverse events related to intravenous immunoglobulin therapy in immunodeficiency states

    Article • Allergy and Asthma Proceedings, November 2006, Oceanside Publications Inc.

    Dr Richard L Wasserman

  55. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study

    Article • Annals of Allergy Asthma & Immunology, June 2006, Elsevier

    Dr Richard L Wasserman

  56. Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency

    Article • Journal of Clinical Immunology, May 2006, Springer Science + Business Media

    Dr Richard L Wasserman

  57. Stable Enterovirus 5′ Nontranslated Region over a 7‐Year Period in a Patient with Agammaglobulinemia and Chronic Infection

    Article • The Journal of Infectious Diseases, July 2000, Oxford University Press (OUP)

    Dr Richard L Wasserman, Dr Jim Dunn

  58. Evaluating children with respiratory tract infections: the role of immunization with bacterial polysaccharide vaccine

    Article • The Pediatric Infectious Disease Journal, February 1999, Wolters Kluwer Health

    Dr Richard L Wasserman

  59. Immunodeficiencies

    Article • Current Opinion in Otolaryngology & Head & Neck Surgery, April 1994, Wolters Kluwer Health

    Dr Richard L Wasserman

  60. Chronic Sinusitis as a Manifestation of Primary Immunodeficiency in Adults

    Article • American Journal of Rhinology and Allergy, January 1994, Oceanside Publications Inc.

    Dr Richard L Wasserman

  61. Antibody deficiency

    Article • The Pediatric Infectious Disease Journal, June 1990, Wolters Kluwer Health

    Dr Richard L Wasserman

  62. Sir,

    Article • AIDS, May 1990, Wolters Kluwer Health

    Dr Richard L Wasserman

  63. Polymorphisms of Immunologically Relevant Loci in Human Disease.

    Article • Annals of the New York Academy of Sciences, December 1988, Wiley

    Dr Richard L Wasserman

  64. IGG SUBCLASS DETERMINATIONS

    Article • The Pediatric Infectious Disease Journal, April 1988, Wolters Kluwer Health

    Dr Richard L Wasserman

  65. FAILURE OF ANTI-PNEUMOCOCCAL ANTIBODY FORMATION IN PATIENTS WITH COMPLETE IgA DEFICIENCY AND NORMAL IgG LEVELS

    Article • Pediatric Research, April 1987, Springer Science + Business Media

    Dr Richard L Wasserman

  66. HUMAN ANTI-HAPTEN ANTIBODY DIVERSITY DERIVES FROM COMBINATORIAL MECHANISMS EMPLOYING FEW VH GENES AND SEVERAL JH GENES

    Article • Pediatric Research, April 1987, Springer Science + Business Media

    Dr Richard L Wasserman

  67. Intravenous gamma globulin prophylaxis for newborn infants

    Article • The Pediatric Infectious Disease Journal, November 1986, Wolters Kluwer Health

    Dr Richard L Wasserman

  68. In vitro stimulation prior to fusion generates antigen-binding human-human hybridomas

    Article • Journal of Immunological Methods, November 1986, Elsevier

    Dr Richard L Wasserman

  69. Ataxia-telangiectasia Associated with Sarcoidosis

    Article • Pediatric Dermatology, September 1986, Wiley

    Dr Richard L Wasserman

  70. Reply

    Article • The Journal of Pediatrics, January 1986, Elsevier

    Dr Richard L Wasserman

  71. Caustic substance injuries

    Article • The Journal of Pediatrics, August 1985, Elsevier

    Dr Richard L Wasserman

  72. 1035 HUMAN HYBRIDOMA ANTIBODIES SPECIFIC FOR THE GROUP B STREPTOCOCCAL TYPE III (GBS-III) POLYSACCHARIDE

    Article • Pediatric Research, April 1985, Springer Science + Business Media

    Dr Richard L Wasserman

  73. Immunology for the Practicing Physician

    Article • The Pediatric Infectious Disease Journal, May 1984, Wolters Kluwer Health

    Dr Richard L Wasserman

  74. IN VITRO SENSITIZATION PRIOR TO FUSION GENERATES A HIGH FREQUENCY OF HUMAN-HUMAN HYBRIDOMAS BINSING TO GROUP B STREPTOCOCCI (GBS)

    Article • Pediatric Research, April 1984, Springer Science + Business Media

    Dr Richard L Wasserman

  75. Transfusion-associated cytomegalovirus infection and acquired immune deficiency syndrome in an infant

    Article • The Journal of Pediatrics, December 1983, Elsevier

    Dr Richard L Wasserman

  76. Unconventional therapies for neonatal sepsis

    Article • The Pediatric Infectious Disease Journal, November 1983, Wolters Kluwer Health

    Dr Richard L Wasserman

  77. The amino acid sequence of the light chain variable region of a canine myeloma immunoglobulin: Evidence that the vk subgroups predated mammalian speciation

    Article • Immunochemistry, May 1978, Elsevier

    Dr Richard L Wasserman

  78. Primary structure of the variable regions of two canine immunoglobulin heavy chains

    Article • Biochemistry, July 1977, American Chemical Society (ACS)

    Dr Richard L Wasserman

  79. Immunoglobulins

    Article • January 1977, Elsevier

    Dr Richard L Wasserman